Literature DB >> 1381911

Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

J Arikawa1, J S Yao, K Yoshimatsu, I Takashima, N Hashimoto.   

Abstract

To investigate the role of Hantaan virus envelope glycoprotein in infection, a panel of monoclonal antibodies (MAbs) was examined in vitro with several serological tests and in vivo by passive transfer experiments in mice. An antigenic site, specific for the inhibition of infected cell focus was detected with the focus inhibition neutralization test (FINT), in addition to the neutralization related antigenic sites, which were revealed by the ordinary focus reduction neutralization test (FRNT). Suckling mice were given the MAbs by passive transfer followed by lethal Hantaan virus challenge. All neutralizing MAbs detected by either FRNT or FINT protected all mice from lethal infection, confirming the importance of the antigenic sites as a protective antigen. Mice given non-neutralizing MAbs by passive transfer, however, began to die earlier than the control group; mean time to death (18.2 +/- 2.1 to 21.5 +/- 2.8 days) being significantly shorter than that of the control group (25.8 +/- 1.8, p less than 0.01, Mann-Whitney, U probability test). Virus titers in brains of mice which died early, were about 10 times higher than those of control mice. These results indicated the early death phenomenon of mice which was mediated by the anti-virus antibody.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381911      PMCID: PMC7087150          DOI: 10.1007/bf01309700

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  34 in total

1.  Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus.

Authors:  C H Tan; E H Yap; M Singh; V Deubel; Y C Chan
Journal:  J Gen Virol       Date:  1990-03       Impact factor: 3.891

2.  Antigenic difference between viral strains causing classical and mild types of epidemic hemorrhagic fever with renal syndrome in China.

Authors:  G Song; C S Hang; H X Liao; J L Fu; G Z Gao; H L Qiu; Q F Zhang
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

3.  A preliminary report on hemorrhagic fever with renal syndrome in China.

Authors:  Y T Jiang
Journal:  Chin Med J (Engl)       Date:  1983-04       Impact factor: 2.628

4.  Evaluation of focus reduction neutralization test with peroxidase-antiperoxidase staining technique for hemorrhagic fever with renal syndrome virus.

Authors:  O Tanishita; Y Takahashi; Y Okuno; K Yamanishi; M Takahashi
Journal:  J Clin Microbiol       Date:  1984-12       Impact factor: 5.948

5.  Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies.

Authors:  J Arikawa; A L Schmaljohn; J M Dalrymple; C S Schmaljohn
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

6.  Clinical and serological diagnosis of Nephropathia epidemica, the mild type of haemorrhagic fever with renal syndrome.

Authors:  J Lähdevirta; J Savola; M Brummer-Korvenkontio; R Berndt; R Illikainen; A Vaheri
Journal:  J Infect       Date:  1984-11       Impact factor: 6.072

7.  Isolation of haemorrhagic fever with renal syndrome virus from leukocytes of rats and virus replication in cultures of rat and human macrophages.

Authors:  T Nagai; O Tanishita; Y Takahashi; T Yamanouchi; K Domae; K Kondo; J R Dantas; M Takahashi; K Yamanishi
Journal:  J Gen Virol       Date:  1985-06       Impact factor: 3.891

8.  Immune spleen cell-mediated protection against fatal Hantaan virus infection in infant mice.

Authors:  T Nakamura; R Yanagihara; C J Gibbs; D C Gajdusek
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

9.  Monoclonal antibodies specific for Hantaan virus.

Authors:  M C Franko; C J Gibbs; P W Lee; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever.

Authors:  R C Weiss; F W Scott
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1981       Impact factor: 2.268

View more
  23 in total

Review 1.  The Syrian hamster model of hantavirus pulmonary syndrome.

Authors:  David Safronetz; Hideki Ebihara; Heinz Feldmann; Jay W Hooper
Journal:  Antiviral Res       Date:  2012-06-15       Impact factor: 5.970

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

3.  Phage-displayed peptide targeting on the Puumala hantavirus neutralization site.

Authors:  T Heiskanen; A Lundkvist; A Vaheri; H Lankinen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro.

Authors:  Shuyang Yu; Mifang Liang; Baoliang Fan; Hongtao Xu; Chuan Li; Quanfu Zhang; Dexin Li; Bo Tang; Shijie Li; Yunping Dai; Meili Wang; Min Zheng; Bingxue Yan; Qinghong Zhu; Ning Li
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence.

Authors:  H Ebihara; K Yoshimatsu; M Ogino; K Araki; Y Ami; H Kariwa; I Takashima; D Li; J Arikawa
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

Authors:  J W Hooper; D M Custer; E Thompson; C S Schmaljohn
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.

Authors:  D M Custer; E Thompson; C S Schmaljohn; T G Ksiazek; J W Hooper
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  New York 1 and Sin Nombre viruses are serotypically distinct viruses associated with hantavirus pulmonary syndrome.

Authors:  I Gavrilovskaya; R LaMonica; M E Fay; B Hjelle; C Schmaljohn; R Shaw; E R Mackow
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

9.  A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Authors:  Jay W Hooper; Matthew Josleyn; John Ballantyne; Rebecca Brocato
Journal:  Vaccine       Date:  2013-07-24       Impact factor: 3.641

10.  Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome.

Authors:  S Jenison; T Yamada; C Morris; B Anderson; N Torrez-Martinez; N Keller; B Hjelle
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.